History
Amyotrophic lateral sclerosis (ALS) is a degenerative neurological disease in which the nerve cells responsible for movement gradually disappear, causing the muscles to weaken and waste away. Today it is commonly called ALS, but historically it has been understood within the larger category of motor neuron diseases. Records of a similar clinical picture already existed in the early 19th century; in 1869, Charcot systematically described the link between the symptoms and lesions of the nervous system, and in the 1870s the name "amyotrophic lateral sclerosis" became established. For several decades afterward, the cause of the disease remained almost entirely unknown, so diagnosis relied on observing the clinical course and ruling out other diseases.
A major change in the history of treatment began with the introduction of riluzole in the 1990s. Although it is not a cure, the fact that it could slightly slow the progression of the disease created the goal of "disease modification." Edaravone was added in the 2010s, and more recently, as gene-targeted therapies have entered clinical practice for specific genotypes (e.g., SOD1 mutations), ALS treatment has been shifting away from "one drug for everyone" toward "adding treatments tailored to the subtype."
Recent research emphasizes that the systematic provision of symptomatic care (breathing, nutrition, communication, and rehabilitation) has a major impact on survival and quality of life, and at the same time highlights a trend toward strengthening early diagnosis and personalized treatment based on genetic and protein markers.
Causes
The cause of ALS cannot be reduced to a single factor. About 90-95% of all cases are classified as sporadic, in which no clear single cause can be found, and 5-10% are classified as hereditary (familial), in which there is a family history or a genetic variant is identified. It is thought that even in sporadic cases, genetic predisposition and environmental factors may act together.
Age, male sex, certain environmental exposures (heavy metals, organic chemicals, smoking), electrical injury, and head trauma have repeatedly been cited as risk factors in research, but the cause-and-effect relationship is not clear enough to say that an individual can "prevent it just by avoiding this." Ultimately, in clinical practice the "cause" is explained in two broad layers. The first is genetic causes (specific gene variants), and the second is complex causes that have not yet been precisely identified.
Recent research emphasizes the view that ALS is not simply a problem of motor neurons alone, but a multistep disease in which several processes are disrupted together, including glial cells, immune and inflammatory responses, protein-handling systems, mitochondrial function, and axonal transport. In particular, it is frequently explained that abnormal protein clumping and neuroinflammation can influence each other and accelerate progression.
Genetic Epidemiology
The key point in the genetic epidemiology of ALS is that "some of all patients have a clear genetic type." Many genes can be involved in hereditary ALS, and pathogenic variants are sometimes found in some sporadic cases as well. Well-known genes include the C9orf72 repeat expansion, SOD1, FUS, and TARDBP. These major genes can account for a substantial portion of hereditary cases, but they do not explain all genetic cases.
An important fact in genetic epidemiology is that "the genotype can change the prognosis and treatment choices." For example, gene-targeted therapies such as tofersen are being discussed for SOD1-related ALS, and certain genotypes may be associated with cognitive and behavioral changes or with the rate of progression.
Recent research emphasizes that it is clinically important to improve access to genetic testing and to have a system for interpreting test results together with genetic counseling for patients. Because most patients have no clear family history and genes do not explain everything, it is realistic to understand ALS as "in some cases a single gene, but in many cases a mix of multiple genetic predispositions and environmental factors."
General Epidemiology
ALS is a rare disease, but it is known to be the most common form among motor neuron diseases. Incidence and prevalence vary by region and research method, but an annual incidence of roughly 1-2 people per 100,000 population is often cited. Onset is most common between ages 45 and 75, and the average age of onset is often described as around 60.
Clinically, ALS is divided according to where it first begins into "limb-onset" and "bulbar-onset (beginning with speech and swallowing)." Limb-onset is more common, and bulbar-onset tends to have a worse prognosis. Some cases begin with respiratory symptoms, but this is rare. In addition, because sensory nerves are relatively preserved in many cases of ALS, it tends to be perceived as "a disease in which strength is lost and muscles shrink" rather than "a disease that hurts and dulls sensation."
Survival varies widely, but on average 2-4 years after symptom onset is frequently cited, and about 10% survive for more than 10 years. Recent research repeatedly emphasizes that respiratory support (noninvasive ventilation), nutritional support (gastrostomy tube), and multidisciplinary care can meaningfully improve survival and quality of life.
Pathogenesis
The pathogenesis of ALS is explained not as a single pathway but as a "complex network" in which multiple forms of damage overlap. At its center is the progressive loss of upper and lower motor neurons; as a result, the signals that move the muscles weaken and the muscles atrophy.
In recent research, "breakdown of protein homeostasis" in particular is treated as an important axis. The concept is that proteins that should normally be cleared within the cell are not processed properly and clump together, and this interferes with cell function. A representative example frequently mentioned is the abnormal relocation and aggregation of the TDP-43 protein. In addition, mechanisms such as decreased function of the mitochondria (the cell's energy factories), oxidative stress, glutamate excitotoxicity, impaired axonal transport, and abnormal RNA metabolism are discussed together.
Inflammation and immune responses are also cited as important factors. Recent research emphasizes the view that TDP-43 abnormalities may be linked to immune and inflammatory pathways, and that the environment surrounding nerve cells (the response of glial cells) can determine the survival of nerve cells. Because of these complex mechanisms, it is difficult to stop the disease completely with any single treatment, and a combination of subtype-specific targeted therapy and symptomatic treatment is presented as a realistic strategy.
Symptoms
The symptoms of ALS center on "decline in motor function." In the early stage, it may begin with subtle weakness, such as one hand feeling clumsy or frequently dropping objects, or it may begin with one leg dragging or the foot catching easily. This may be accompanied by a sensation of muscle twitching (fasciculations), cramps, and a feeling of the muscles wasting away (muscle atrophy).
Bulbar-onset ALS begins with symptoms such as slurred speech (dysarthria) and difficulty swallowing saliva or getting food down (dysphagia). Over time it spreads to the arms and legs, and eventually daily activities, walking, and use of the hands become difficult. When the respiratory muscles weaken, patients become short of breath, may not feel refreshed even after sleeping at night or may develop headaches, and have difficulty coughing up phlegm because their cough becomes weak. This stage is very important because it is directly linked to survival.
In a considerable number of patients, changes in thinking, personality, and behavior may occur, and some may progress to frontotemporal dementia. Because these changes have a major impact on the family's caregiving burden and on decision-making, explanation and preparation are needed early on. Sensation (pain, touch) is relatively preserved in many cases, but pain itself can commonly occur due to restricted movement, changes in posture, and muscle cramps.
Signs
The key signs seen on examination are a combination of upper motor neuron signs and lower motor neuron signs appearing together. Upper motor neuron signs can appear as stiffening of the muscles (spasticity), exaggerated reflexes, and findings such as ankle clonus. Typical lower motor neuron signs are muscle weakness, muscle atrophy, and fasciculations that ripple beneath the skin.
When there is bulbar involvement, pronunciation may become inaccurate, the tongue may become thin or sluggish in movement, and the swallowing response may weaken. As the disease progresses, weight loss, worsening nutritional status, and declining respiratory function appear as signs.
Electrophysiological testing (electromyography and nerve conduction studies) can confirm findings that appear when the nerves supplying the muscles are damaged, and this serves to support the clinical signs. Imaging is often more important for ruling out other conditions (such as nerve compression in the neck or lower back).
Screening
There is no population-based screening test for the general public. Instead, quickly recognizing "unexplained progressive muscle weakness" in everyday practice effectively serves as screening. In particular, neurological evaluation is needed in cases with 1) weakness that begins on one side and gradually spreads, 2) muscle atrophy and fasciculations, 3) a pattern in which only motor function declines while sensation is relatively intact, and 4) accompanying speech and swallowing problems.
At the screening stage, rather than confirming ALS itself, other conditions that produce similar symptoms are also kept in mind. Examples include polyneuropathy, compression neuropathy, myasthenia gravis, neck and lower back disorders, certain muscle diseases, and multiple sclerosis. Therefore, the key is to refer the patient to specialist care without delay when "rapidly progressing motor weakness" is seen.
In recent research, nerve damage markers in the blood or cerebrospinal fluid (e.g., neurofilament), genetic testing, and digital assessments (tracking functional scores) are attracting attention as tools that aid early diagnosis and prediction of the disease course. However, in current clinical practice, the most important screening is still the medical history and neurological examination.
Diagnosis
The diagnosis of ALS is largely a "clinical diagnosis + diagnosis of exclusion." It is diagnosed when upper and lower motor neurons are progressively involved and there is no other disease that explains this pattern. Electromyography is very important in the diagnostic process. Electromyography confirms findings of denervation in multiple muscles, supporting the fact that the disease is not a problem confined to one area.
Blood tests and imaging (magnetic resonance imaging of the brain and spinal cord) are performed to rule out other causes. If necessary, genetic testing is used to identify specific genotypes (e.g., SOD1, C9orf72), and this can influence family counseling and some treatment choices.
For functional assessment, scoring systems such as the revised ALS Functional Rating Scale are used to track the rate of progression. In recent research, markers such as neurofilament may be associated with the rate of progression, and there is a growing movement to use them in diagnosis and in the evaluation of clinical trials.
Treatment
Treatment consists of 1) drug therapy to slow progression, 2) symptomatic treatment including breathing, nutrition, communication, and rehabilitation, and 3) a multidisciplinary team approach. Riluzole is a drug that works by reducing glutamate excitotoxicity and is known to modestly prolong survival. Edaravone is a drug that reduces oxidative stress and is known to slow the rate of functional decline in some patients. For specific genotypes (SOD1-related), tofersen can be used as a gene-targeted therapy.
In respiratory care, noninvasive ventilation is very important because it can reduce shortness of breath and sleep problems and prolong survival. Cough assistance and secretion management are also key to delaying infection and respiratory failure. In terms of nutritional therapy, because weight loss can worsen progression, dietary adjustment and, when necessary, nutritional support such as a gastrostomy tube (percutaneous endoscopic gastrostomy) are considered when swallowing function declines. Walking aids, wheelchairs, hand function aids, communication assistive devices, and speech therapy are important for maintaining function and quality of life.
Recent research repeatedly emphasizes that this kind of "supportive care" has as great an impact on survival and daily function as medication does. Combining subtype-specific targeted therapy with systematic symptom management is the current direction of treatment.
Prognosis
Prognosis varies greatly between individuals, but on average progression tends to be rapid. Survival of 2-4 years after symptom onset is commonly cited; some survive 5-10 years or longer, and about 10% survive for more than 10 years. Factors that affect prognosis include age at onset, site of onset (bulbar-onset is unfavorable), rate of progression, timing of respiratory decline, presence of accompanying cognitive and behavioral changes, and genotype.
The most common direct cause of death is respiratory failure, which can be accelerated by pneumonia. Therefore, prognosis is not determined simply by nerve cell damage alone and can vary greatly depending on maintenance of nutrition, timing of the introduction of respiratory support, infection prevention, and the level of multidisciplinary management.
Recent research repeatedly reports that noninvasive ventilation and nutritional support can prolong survival, and "early planning" is emphasized as a practical factor that can change the prognosis. It is important to make plans for breathing, nutrition, rehabilitation, and communication together with a multidisciplinary team from the early stage of diagnosis.
Prevention
There is no way to reliably prevent ALS. This is because most ALS is sporadic and its cause cannot be reduced to a single lifestyle factor. Even in hereditary ALS, having a gene variant does not make it possible to accurately predict the timing and form of onset. Therefore, it is realistic to understand prevention as "preventing complications and minimizing risk" rather than "preventing onset."
First, if progressive muscle weakness, speech and swallowing problems, or respiratory symptoms appear, it is important to be evaluated quickly so that diagnosis is not delayed. Second, after diagnosis, maintain weight and nutrition, have respiratory function assessed regularly, and introduce noninvasive ventilation and cough assistance at the appropriate time to prevent pneumonia and respiratory failure. Third, adjust the home environment and assistive devices to prevent secondary injuries such as falls and pressure sores.
Recent research emphasizes that as genotype-based treatments expand, genetic counseling and testing in cases with a family history or early onset play an important role in "early preparation" rather than "prevention." Meeting a specialist team early and making a plan is the most practical preparation for both patients and families.